Login to Your Account



Novartis shoots a hoop with Ilaris in cardiovascular outcomes study

By Cormac Sheridan
Staff Writer

Thursday, June 22, 2017

DUBLIN – Novartis AG looks to be on course to add another significant product to its portfolio of cardiovascular drugs following a positive readout from the Cantos phase III trial of its IL-beta1 inhibitor, Ilaris.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription